Tokyo-based Eisai has been granted marketing authorization approval in Japan for an OTC version of its Pariet-branded proton pump inhibitor for stomach pain, heartburn and bloating.
Eisai Switches Proton Pump Inhibitor Rabeprazole To OTC In Japan
Eisai aims to support people in Japan with severe heartburn and discomfort caused by gastric acid related conditions by switching from prescription to OTC status its Pariet-branded proton pump inhibitor.
